Abstract
Hypertension is a common comorbidity in patients with Type 2 Diabetes Mellitus (T2DM). One of the new anti-diabetic classes is Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor which is still widely tested in clinical trials for indications beyond T2DM. However, the effect on blood pressure in T2DM patients receiving SGLT2 inhibitors is still not well known. This study wants to find out the effect of Dapagliflozin on blood pressure in patients with T2DM. This study was conducted on 1–7 January 2023. Two independent researchers systematically extracted data from several databases, such as PubMed Central (PMC), Science Direct, and PUBMED by using MeSH terminology of keywords SGLT2 inhibitor and blood pressure. The extracted studies were then analyzed and selected according to our inclusion criteria such as studies in the last 5 years, T2DM patients receiving dapagliflozin, cohort studies, and case-control studies. We excluded systematic reviews, meta-analyses, case series, case reports, studies on pregnant women, children, and animals. Research quality was assessed using Newcastle-Ottawa (NOS). From 4 cohort studies (1664 subjects from various countries), all of them showed dapagliflozin administration resulted in reduction of systolic blood pressure. In some studies, the blood pressure-lowering effect of dapagliflozin administration was greater when combined with other classes of anti-diabetic drugs like Glucagon-Like Peptide-1 (GLP1) agonist; All studies have proven good quality based on NOS. In conclusion, dapagliflozin had a blood pressure-lowering effect in T2DM patients. However, further study is needed to confirm these findings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
